Psilocybin and Inflammatory and Mitochondrial Stress Markers in Parkinson Disease
Abstract
This nonrandomized clinical trial assesses associations between psilocybin therapy and changes in systemic markers of inflammation and mitochondrial stress in people with Parkinson disease and mood dysfunction.
// Source
Authors: Ellen Bradley, Parker Kelley, Balázs Szigeti, Kristen M. Nishimi, Martin A. Picard, Kimberly Sakai, Gisele Fernandes‐Osterhold, Jill L. Ostrem, Caroline M. Tanner, Connie Ludwig, Katiah Llerena, Patrick R. Finley, Zachary Busby, Amber McKernan, Madeline M. Pantoni, Andrew Penn, Aliss C.C. Wang, Jose Rafael Pantoja Zuzuarregui, Joshua D. Woolley, Aoife O’Donovan
Institutions: Imperial College London, University of California, San Francisco, Columbia University Irving Medical Center, New York State Psychiatric Institute, Laguna Research, San Francisco VA Medical Center